Document text
Principal Investigator: Robert Tarran
Organization: ELDEC PHARMACEUTICALS, INC.
Fiscal Year: 2022
Award: $300,000
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
COVID-19 is caused by inhalation of the latest coronavirus (CoV) SARS-CoV-2 into the lungs, and airway
epithelia are particularly susceptible to uptake this virus. Extensive evidence indicates that angiotensin
converting enzyme 2 (ACE2) binds to the S1 subunit of the SARS-CoV-2 Spike protein (S1), triggering selective
proteolytic cleavage that liberates the S2 subunit. S2 undergoes extensive conformational changes to form a 6-
helix bundle (6-HB) between Heptad Repeat (HR)-1 and HR-2 domains of S2, which ultimately results in the
fusion of the viral particle with the cell membrane and subsequent viral entry. Based on the mechanism of viral
entry, and supported by crystallography studies of the ACE2•S1 interface and the 6-HB complex of S2, enormous
efforts are currently under way to develop peptide-based therapeutics to target both events: the interaction of
SARS-CoV-2 Spike with ACE2 receptor, and the fusion of the viral particle to the cell membrane. We have
discovered that exposure of well-differentiated, primary airway epithelial cultures to tobacco smoke for extended
periods of time enhances ACE2 activity and increases binding of recombinant S1, which might explain the
increased susceptibility of smokers to COVID-19. The Receptor Binding Domain (RBD) in S1 is part of a highly
mutable region, as revealed by the appearance of multiple highly infectious SARS-CoV-2 variants in late 2020;
thus, targeting this region might not be ideal for antiviral development. In contrast, the HR regions of the S2
subunit and the interaction mode of HR-1 and HR-2 domains within the 6-HB complex are highly conserved
among various CoVs, which makes it an optimal target to develop broad-spectrum antivirals. EK1 is a peptide
that. The goal of this application is to develop novel peptides that target the HR1 domain of the S2 subunit to
inhibit membrane fusion and pseudovirus infection of SARS-CoV-2 as well as several other CoVs. These
peptides should serve as broad-spectrum CoV antivirals for the treatment of COVID-19 and subsequent COVIDs.
We propose to evaluate the proteolytic stability of several peptides in the hostile environment of the lung, as the
main entry way of SARS-CoV-2, including stapled and N-capped peptides with enhanced helical constraint. We
will measure the proteolytic stability of the peptides ex vivo using human lung secretions obtained from smokers
and non-smokers. We will use primary airway epithelial cells to interrogate the ability of the peptides to inhibit
fusion and SARS-CoV-2 pseudovirus infection to healthy and smoke-exposed airway cultures. The efficacy of
these peptides will be ultimately evaluated in animal models. This study will address the feasibility of helical
mimics to inhibit viral fusion and suppress viral entry into airway epithelia as a novel effective treatment against
COVID-19.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Aerosols><Affinity><Airway infections><Angiotensin Receptor><Animal Model><Animal Models and Related Studies><Antiviral Agents><Antiviral Drugs><Antivirals><Appearance><Back><Binding><Binding Proteins><Bioavailability><Biologic Availability><Biological Availability><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Bronchioalveolar Lavage><Bronchoalveolar Lavage><Bronchopulmonary Lavage><COVID><COVID-19><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cell Function><Cell Process><Cell membrane><Cell physiology><Cell surface><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemicals><Chemistry><CoV anti-viral><CoV antiviral><CoV disease><CoV emergence><CoV-2><CoV2><Collaborations><Complex><Consensus Sequence><Coronaviridae><Coronavirus><Crystallographies><Crystallography><Cytoplasmic Membrane><Disease><Disorder><Doctor of Philosophy><Dorsum><Effectiveness><Eldec><Environment><Enzyme Gene><Enzymes><Epithelial><Epithelial Cells><Ero Test><Esteroproteases><Estratest><Event><Formulation><Glosso-Sterandryl><Glycoproteins><Goals><Granulocyte Elastase><Guidelines><HIV><HR1 Domain><Head><Hr1 Repeat><Human><Human Immunodeficiency Viruses><Immunology><In Vitro><Infection><Infection prevention><Inflammation><Inhalation><Inhalators><Inhaler><Inhaling><Institutes><LAV-HTLV-III><Lead><Leukocyte Elastase><Ligand Binding Protein><Ligand Binding Protein Gene><Lung><Lung Lavage><Lung Respiratory System><Lymphadenopathy-Associated Virus><Lysosomal Elastase><Lytotoxicity><Malogen><Marrow Neutrophil><Measures><Medicine><Membrane Fusion><Metandren><Mice><Mice Mammals><Microbiology><Modeling><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Murine><Mus><Nebulizer><Neohombreol M><Neutrophil Elastase><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Orchisterone-M><Oreton methyl><PMN Elastase><Pathogenicity><Pathway interactions><Patients><Pattern><Pb element><Peptidases><Peptide Hydrolases><Peptides><Persons><Ph.D.><PhD><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacology><Phase><Physiologic Availability><Plasma Membrane><Pneumonia><Polymorphonuclear Cell><Polymorphonuclear Leukocyte Elastase><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Powder dose form><Powders><Predisposition><Prevent infection><Primary Infection><Process><Protease Gene><Proteases><Protein Binding><Proteinases><Proteins><Proteolytic Clipping><Proteolytic Enzymes><Proteolytic Processing><REM Repeat><RHO Effector Domain><Receptor Protein><Recombinants><Reproducibility><Research><Resistance><Respiratory Epithelium><Respiratory Infections><Respiratory Tract Infections><Risk><Role><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV disease><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Smoke><Smoker><Structure of respiratory epithelium><Subcellular Process><Surface><Susceptibility><Techniques><Testing><Testomet><Testotonic B><Testovis><Testred><Therapeutic><Time><Tobacco smoke><Transgenic Mice><VSV><Variant><Variation><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Diseases><Virus><Virus Diseases><Virus-HIV><Work><Wuhan coronavirus><airway epithelium><analog><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral compound><antiviral development><antiviral drug development><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><base><bound protein><bronchial epithelium><bronchopulmonary lavage therapy><cigarette smoke exposure><conformation><conformational state><corona virus><corona virus disease><corona virus disease 2019><corona virus emergence><coronavirus anti-viral><coronavirus antiviral><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><cytotoxicity><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><disease severity><effective therapy><effective treatment><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><exposure to cigarette smoke><hCoV19><heavy metal Pb><heavy metal lead><immunogenicity><improved><in vivo><inhibitor><lead optimization><model of animal><model organism><nCoV><nCoV2><neutrophil><new CoV><new corona virus><new coronavirus><non-smoker><nonsmoker><novel><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><particle><pathway><peptide mimetic><peptide mimic><peptidomimetics><plasmalemma><prevent><preventing><professor><pulmonary><receptor><receptor binding><receptor bound><resistant><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><social role><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><uptake><viral infection><virus infection><virus-induced disease>